secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001437749-22-010872
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports Q1 2022 cash burn of $3.9M; ReMEDy2 stroke trial sites more than double
--------------------------------------------------------------------------------

- Cash & investments $41M at March 31 (Dec 31: $45.1M); working capital $40.7M; cash runway into 2024.
- Net cash used in ops $3.9M (Q1 2021: $4.3M); R&D exp $2.0M (-$0.4M); G&A exp $1.6M (+$0.4M).
- ReMEDy2 stroke trial active sites more than doubled to 9; slower enrollment due to COVID staffing & discharge logistics.
- REDUX CKD trial fully enrolled (79 patients); last visit in March 2022; final analysis ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/0001437749-22-010872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/dmtp20220503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-010872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer